Medtronic Q2 Earnings Call In Brief
This article was originally published in The Gray Sheet
Executive Summary
Endeavor DES: Medtronic is on track to file IDE for Endeavor III confirmatory study in the "next few weeks and begin [a] study here in the U.S. in late December," Medtronic CEO Art Collins tells investors Nov. 12, during a quarterly earnings call. The Endeavor II pivotal trial has crossed its midway point, with 600 of 1200 patients enrolled, the exec also notes, commenting that safety and toxicity data for the firm's ABT-578 drug compound are favorable. Medtronic continues to forecast a European DES launch in late 2004 and a U.S. release at the end of 2005 (1"The Gray Sheet" September 22, 2003, p. 8)....
You may also be interested in...
Medtronic Endeavor DES 4-Month Data Bode Well For Pivotal Studies – Firm
Medtronic is taking heart from Boston Scientific's TAXUS IV paclitaxel-eluting stent study results indicating that a late lumen loss of 0.39 mm in-stent was associated with an 8% restenosis rate
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.